Navigation Links
New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas' V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
Date:5/2/2013

p>1

The primary objective of the observational study was to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the categories of baseline treatment. Patients in the study were followed on their current therapy for up to 6 weeks before starting the V-Go insulin delivery device. The study, observational in nature, has no mandated or forced titration instructions to guide insulin therapy with the exception of starting doses for V-Go basal rate options.1

The interim analysis of the observational study suggests that 47 patients had continuous V-Go use for a minimum of 3 months. Most of the patients in the study were men with an average age of 60 having diabetes for 13 years. At the time of this interim analysis, A1C levels for the study participants reduced from 9.0 percent to 8.6 percent during the 4 to 6 week run-in phase. After the run-in period and starting the V-Go, the interim results suggest that patient A1C levels further improved with a mean change from 8.6 percent to 7.8 percent; P<0.0001 from month 0 to month 3. Five patients reported adverse events probably related to V-Go (primarily rash or skin irritation). Six patients reported hypoglycemia <70 mg/dL. There was no significant change in weight. Additionally, total daily insulin dose was reduced by 19 percent (12.5 units) on average.1

About Diabetes

In order to fuel the human body's cells with glucose, or sugar, insulin is required. While the body continuously produces insulin, people with Type 2 diabetes, the most common form of diabetes, either do not produce enough insulin, or their bodies cannot use the insulin adequately. When there is not enough, or insulin is not used properly, glucose builds up in the blood instead of going into the body's cells. If not controlled properly, diabetes can increase the risk of heart disease, blindness, amputati
'/>"/>

SOURCE Valeritas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
2. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
3. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
4. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. Sihuan Pharmaceutical Announces 2012 Interim Results
7. Medical Marijuana Inc. Announces Ted Caligiuri as Interim President and CEO
8. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
9. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
10. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
11. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...
... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...
Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:3/5/2015)... East Providence, RI (PRWEB) March 05, 2015 ... for a third year in a row to support the ... cancer. The donation covered the purchase of the ‘Think ... Out’ game against Big East Conference opponent DePaul University at ... is pleased to continue our support of the PC women’s ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 In honor ... to shatter myths about drug and alcohol abuse in ... released a Fact Sheet with information on some of ... in 2010 by the National Institute on Drug Abuse, ... alcohol aims to counteract the illusions that teens and ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Nutrition Leaders, ... products, is pleased to offer reformulated Millennium 500 Creatine ... Millennium 500 is a German grade creatine supplement that ... promote muscle recovery, and aid with overall strength gains ... that acts as a reserve energy source in the ...
Breaking Medicine News(10 mins):Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2
... a study done by Kate Rittenhouse-Olson, Ph.D., the monoclonal antibody ... shown to extend// significantly the survival of mice with human ... antibody inhibits the cancer's spread to the lungs in the ... study were published in the November 2006 issue of Journal ...
... of height which happens as people catch up with age is ... which could have major repercussions on health, increasing the chances of ... of about 3 centimeters or more in height of men as ... compared to men who lose less than a centimeter. This risk ...
... Researchers from University of Queensland believe that the conotoxins ... treatment for sufferers from chronic pain//. This treatment could ... ,Researchers say that the toxin, snail uses ... the severe side effects usually caused by other pain ...
... say that they are not abandoning their quest of finding ... the death of new cholesterol drugs manufactured// by Pfizer. Reducing ... cardiology in recent years, but boosting its counterpart, HDL, also ... market the new drug with Lipitor, a cholesterol-lowering statin that ...
... will now be made more easily available to critically ill ... proposition that will enable patients// who are extremely ill to ... other options. ,The FDA has announced that they ... drugs to be made available to needy individuals .They will ...
... nosed, bleary- eyed Britons, relief from hay fever may ... pill, designed to prevent// allergic reactions like a running nose, itching ... ,The vaccine pill contains small amounts of Timothy grass pollen; main ... weeks before hay fever season. ,This pill follows the ...
Cached Medicine News:Health News:Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies 2Health News:Revolutionary Pill Promises Relief for Hay Fever Sufferers 2
For the quantitative in vitro determination of Transferrin in human serum...
For the quantitative in vitro determination of Transferrin in Serum...
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: